Latest / AVBCC Value-Based Voices / Can the U.S. Keep Its Edge? FDA Policy, China’s Momentum, and the Future of Innovation
Transcript
- 0:00Speaker: Welcome to Value-Based Voices, a podcast from the Association for Value-Based Cancer Care.
- 0:05Speaker: Each episode dives into the shifting terrain of cancer care in the United States, exploring what value means in today's clinical, policy, and patient-centered environments.
- 0:15Speaker: Our mission is to spark informed dialogue, promote transparency, and equip every stakeholder from providers to patients with the insights they need to navigate cancer care with clarity and confidence and purpose.
- 0:28Speaker: My name is Jayson Slotnik, a partner at Health Policy Strategies, an AVBCC board member, and I'll be your host for this episode.
- 0:42Speaker: Today, I'm pleased to be joined by Steve Usdin, Senior Editor at Biocentury Publications and author of the books Bureau of Spies and Engineering Communism.
- 0:53Speaker: And today's episode picks up from episode from a previous episode where we discuss the history, the recent history of FDA and its political ramifications.
- 1:03Speaker: On part two of this podcast, you will hear Steve's thoughts about well, what is the future of the FDA?
- 1:11Speaker: What is the FDA doing as it relates to competition with China?
- 1:15Speaker: What is the FDA doing as it relates to improving clinical trials?
- 1:19Speaker: And some thoughts about who the next commissioner could be.
- 1:22Speaker: And really excited to have Steve back for part two.
- 1:25Speaker: Welcome, Steve, and thank you for your time.
- 1:27Speaker: It's been very interesting through my CMS lens with this most favored nation policy what has occurred as an unintended consequence of their most the you know, the administration's most favored nation is a reluctance to launch in Europe because of a European price setting a US price for the market.
- 1:47Speaker: We saw that Amgen pulled out.
- 1:49Speaker: We've seen other companies publicly state that just sort of gonna hold off a little bit.
- 1:54Speaker: Now China's stepping into the void.
- 1:56Speaker: So the the Chinese the China um growth of China and using uh drugs and and having them replace or surplant us as the leader in biotech, it it is a real problem.
- 2:09Speaker: Is what else can FDA be doing, right?
- 2:13Speaker: I mean, we have a whole different approach to human rights and and protections in this country as compared to China.
- 2:19Speaker: So I don't know that we could ever be on par, but you said it's incremental, but is there something uh other that they should be doing, the FDA?
- 2:27Speaker: Maybe it's not a person human, maybe it's other tools.
- 2:30Speaker: What should they be doing?
- 2:32Speaker 1: I I think a lot of things about this.
- 2:33Speaker 1: So so one, I think that framing China as an adversary and and framing um the life sciences as a zero-sum game is a mistake to start with.
- 2:46Speaker 1: I think that uh having it as a goal that the United States is the best place in the world to develop uh biopharmaceuticals isn't is uh is the right goal, and we should we should try to do that.
- 2:58Speaker 1: But that doesn't mean that that China won't have a role to play and a big role to play uh in biomedical innovation going forward.
- 3:05Speaker 1: It will.
- 3:05Speaker 1: They've made the investments, they um have they've done the hard work.
- 3:10Speaker 1: Um anybody who's been there um comes away tremendously impressed um b by what they've done.
- 3:16Speaker 1: Uh and and that that's just gonna be a factor going forward.
- 3:21Speaker 1: What what I think the first thing that the United States needs to do if they want to prevent the United States from losing um its its preeminent role in the life sciences is to stop shooting ourselves in the foot for the f uh to start with you, okay?
- 3:37Speaker 1: So that has a lot of that has a lot of dimensions to it, okay?
- 3:40Speaker 1: One, uh what's the fundamental basis for advances in the life sciences?
- 3:46Speaker 1: It's basic research that's funded by NIH.
- 3:49Speaker 1: NIH has been the largest and the best funder of basic scientific research in the in the world, bar none for since the Second World War.
- 4:00Speaker 1: We're doing our best to erode all of that, to lose that very quickly, you know, since since January 2025.
- 4:07Speaker 1: The, you know, by any measure, by the amount of grants that are given, the dollars or the numbers of grants, by the uh restrictions on international collaborations, by now by the OMB's latest proposal to politicize science, to say explicitly that no scientific grant, no grant for anything from government, but we're concerned about the sciences, can be given without a political official signing off on it and saying that it's in alignment with the govern with the with the White House's policies.
- 4:39Speaker 1: That's a recipe for um for disaster, right?
- 4:43Speaker 1: And they're also saying that they want to, which by the way, even if you're in alignment with this White House's policies, you have to understand that this administration isn't going to persist forever.
- 4:54Speaker 1: The next one that comes in that you may disagree with completely, um, they're not necessarily going to just say, oh, well, we're not going to use this power.
- 5:02Speaker 1: We've got it, but we're not going to use it.
- 5:03Speaker 1: You know, it's quite likely that they will use it once they've given it.
- 5:05Speaker 1: That's the way that these things work.
- 5:06Speaker 1: There are other things.
- 5:08Speaker 1: So the the OMB rule would make it virtually impossible to have international collaboration.
- 5:14Speaker 1: I don't see how we're going to uh tackle um infectious diseases, Ebola or AIDS or or anything like that um with without collaborating with uh with investigators overseas.
- 5:24Speaker 1: And I don't think that there's anybody who thinks that the United States, even if we have the best science in the United States, we don't have a monopoly on it.
- 5:32Speaker: We don't have the only science, right?
- 5:33Speaker 1: We don't have the only science.
- 5:34Speaker 1: So we we need to collaborate.
- 5:35Speaker 1: Science is a collaborative activity.
- 5:36Speaker 1: There are a lot of other things that are in this um OMB proposal that would really be putting the nail in the coffin of American science.
- 5:44Speaker 1: So that's one thing, okay?
- 5:45Speaker 1: I think immigration policy writ large, it's another thing.
- 5:49Speaker 1: It's underappreciated, but it's really important.
- 5:51Speaker 1: Look, if you go into any biopharma company in the United States, you look around at the executive team or the scientists, and you close your eyes, and you imagine when you open your eyes, everybody who wasn't born in the United States isn't there.
- 6:02Speaker 1: It's gonna look like Swiss cheese, right?
- 6:04Speaker 1: A lot of people are gonna be gone.
- 6:05Speaker 1: And you do it again, you close your eyes again, and you and you when you open them up, everybody whose parents weren't born in the United States isn't there.
- 6:12Speaker 1: Well, you know, that room's gonna be about half empty, right?
- 6:14Speaker 1: Yeah.
- 6:15Speaker 1: Uh so so and but that's that's what's happening.
- 6:18Speaker 1: We're we're making it very difficult for people from other countries to come to the United States, very unattractive for them to come to the United States to study, and then very difficult, if not impossible, for them to stay after they study.
- 6:30Speaker 1: So we've got to change that.
- 6:32Speaker 1: Uh there are a number of other policies.
- 6:34Speaker 1: We've got to have um certainty around um intellectual property, we've got to have certainty around drug pricing.
- 6:42Speaker 1: The fact that you mentioned the the most favored nation deals, the MFN deals, those were secret deals.
- 6:48Speaker 1: We still don't have the the wording for what was in them.
- 6:51Speaker 1: There were secret deals that were cut between the administration and 17 uh pharma CEOs that expire after three years.
- 6:59Speaker 1: You know, is is that the way that the United States government really is supposed to operate?
- 7:04Speaker 1: You know, it doesn't make any sense.
- 7:07Speaker 1: And then we can go back, people have forgotten.
- 7:08Speaker 1: It's not just this administration.
- 7:10Speaker 1: If you go back and you look at the uh Medicare drug price negotiation program, uh, and you look at, for example, the differential and the way that uh small molecules and large molecules are treated under that uh under that program, again, it's completely illogical because what it does is it incentivizes the development of large molecule drugs.
- 7:32Speaker 1: And anybody who would look at it from the point of view of economics, uh from the point of view of patients especially, would say if you were gonna if you were gonna have a policy that preferred one over the other, and I don't think you should, but if you were, you'd want it you'd want small molecules to win out, right?
- 7:49Speaker 1: They're certain to go generic, um, they're much easier for patients to take.
- 7:53Speaker 1: Um and uh manufacture, there's also manufacture, and and they can do things like cross the blood brain barrier much more easily than um than large molecules.
- 8:03Speaker 1: So there's a lot of things that we have to do if we're talking about competition with China, um, that start by stopping this this process of shooting ourselves in the foot, and then there are things that are obvious that could be done um that that would improve things.
- 8:18Speaker 1: There are processes uh you know FDA has to become fluent um uh when it comes to AI, right?
- 8:26Speaker 1: Just like everybody in the world does in our world today does.
- 8:30Speaker 1: And um it the the the focus on first and human trials is excellent, um, but you know, that's the starting point, right?
- 8:37Speaker 1: There's there's phase two trials and phase three trials.
- 8:40Speaker 1: Um so there has to be uh uh you know reforms that are done there that reforms done to make the regulatory system more transparent, more predictable.
- 8:48Speaker: So speaking of which, we have a PADUFA, a prescription drug user fee act reauthorization that must be passed by September of 27.
- 8:58Speaker: And as you know, you've covered this for every you've probably covered every single PADUFA in fact.
- 9:04Speaker 1: I think every reauthorization, not the first one, but every reauthorization.
- 9:07Speaker: Um it's a negotiation between the administration and the industry ultimately that needs to be passed by the Congress.
- 9:17Speaker: There have been some negotiations that have gone on already.
- 9:19Speaker: There probably have been some provisions that have already been agreed upon.
- 9:23Speaker: What what is in Padufa?
- 9:26Speaker: What do you like about what's in?
- 9:27Speaker: What do you think needs to go in?
- 9:29Speaker: Uh, and is there a chance of it going in between now and 27?
- 9:35Speaker 1: Yeah, so the deal between industry and FDA is done.
- 9:39Speaker 1: Okay, and it hasn't been made public yet, uh, but it's been done.
- 9:42Speaker 1: I've I've spoken with people who were in the room um for the negotiations for it.
- 9:47Speaker 1: I don't think there's gonna be a lot in there that's gonna surprise people.
- 9:51Speaker 1: Uh, there were efforts to have so-called America First provisions put in there that would have been punitive um toward companies that do their um clinical trials uh in China.
- 10:02Speaker 1: Uh those have been watered down to the effect instead of having punishing companies that do their first and human um clinical trials in China, the new PADUFA agreement gives a um a reward, a kind of a bonus to companies that do their first and human trials in the United States, but it's very modest and it's not going to really affect anything.
- 10:22Speaker 1: So the the real question is what's Congress going to attach to PADUFA, right?
- 10:27Speaker 1: And and there's a lot of discussion about that.
- 10:30Speaker 1: Um, Representative Auchincloss, I mentioned it before, he's uh putting together a package of ideas of how to improve the clinical trials enterprise.
- 10:39Speaker 1: A lot of it is aligned with what's in Operation Trial Blazer, but it goes further.
- 10:44Speaker 1: But you know, there's there's gonna be a lot more ideas.
- 10:46Speaker 1: Everything that anybody wants to do, any agenda that anybody has to do that's either at FDA or adjacent to FDA, they're gonna be bringing it up.
- 10:54Speaker: Um in the Do you think there's some uh so right, we call that a Christmas tree, right?
- 11:00Speaker: A bus-based piece of legislation.
- 11:02Speaker: Through my lens, what what I think about is to your point about the MFN deals, as some kind of codification of some of those provisions, which are a commitment to not launch XUS at a lower price than the United States.
- 11:16Speaker: That was part of the MFN deal, or importing a external, you know, an MFN uh most favored nation price uh here, or what could that none of that I think we can get through the Congress, but a for taking price into consideration for FDA approval.
- 11:35Speaker 1: I don't I think look, there's a there's a strong constituency for doing all of those things, but I don't think that any of them can get through.
- 11:42Speaker 1: Okay.
- 11:43Speaker 1: Um but but uh I do think that there's an appetite for further price controls, uh pharmaceutical price controls in the United States, and a lot is gonna depend on um control of the Congress.
- 11:56Speaker 1: The pundits think that the Democrats will get control of the House, the Senate is up for grabs, um, we don't know what's gonna happen there.
- 12:04Speaker 1: But if you it and it really depends on kind of the um the attitude of the Democrats if they get control of either House of Congress.
- 12:14Speaker 1: Because if you were to make a Ven diagram in the UK, you say this is what the Democrats want on drug pricing, and this is what the Republicans want or the White House wants, there is an overlap.
- 12:24Speaker 1: There's an area of agreement uh for things that, and most of those are things that the biopharmaceutical industry uh intensely dislikes and and wouldn't wouldn't want to have happen.
- 12:34Speaker 1: The question is, do we have an appetite for finding that happy middle where people agree?
- 12:40Speaker 1: I don't know if it's a happy middle, but anyway, that that middle of that Venn diagram where people agree, or do do both sides really just want to stake out positions as being the opposite of the other one?
- 12:51Speaker 1: So, you know, if we were back in the day, you know, when you and I started off doing this and you had people like Warren Hatch and Um Ted Kennedy in the in the Senate, or you know, Waxman in the House, when you had people like that, they were looking for that center of the Venn diagram, right?
- 13:06Speaker 1: And they would they would come at it from different positions, but they would try to find that something that they agreed on and pass it.
- 13:13Speaker 1: I don't think that we actually have um much of an appetite for that kind of um deal making, that kind of consensus around um highly divisive issues like drug pricing today.
- 13:27Speaker 1: So I think that what's more likely to happen is either nothing or something that's kind of extreme that gets slipped in as part of a deal-making process um, you know, in the in the middle, you know, the middle of the night, uh the night before something goes to the floor or something like that.
- 13:42Speaker 1: You know, you've seen that, right?
- 13:43Speaker: Yes, right.
- 13:44Speaker: So so Steve, as so cover the FDA.
- 13:47Speaker: I want to change your thinking to you are a physician, you're an oncologist.
- 13:54Speaker 1: No, I'm not.
- 13:55Speaker: And you you give the give the oncologist something to be excited about that's coming in the next six or nine months out of the FDA.
- 14:03Speaker: Is there a new drug?
- 14:05Speaker: Is it like a revolution medicine on pancreatic?
- 14:07Speaker: Is there something that you've been watching develop from a broader nature, a policy level, or maybe uh a drug that's coming back?
- 14:14Speaker: You mentioned adcoms, or those are coming back.
- 14:18Speaker: If you are now on the provider community, what are you what should you what are you telling them right now that gets them excited about new treatments for patients?
- 14:30Speaker 1: If I'd had more time to prepare for this, I'd give you a list because I know that uh, you know, I I cover the policy, my colleagues at at Biocentury cover the therapeutics more closely.
- 14:38Speaker 1: I know that there are things that are exciting.
- 14:41Speaker 1: I'm sure the people who are watching this know it better than certainly know it better than I do.
- 14:45Speaker 1: I think that the question is um whether there's an environment at FDA that's going to give um new oncology products a fair shot.
- 14:55Speaker 1: Because I think there was a there was a sense, and I think it was real, that under uh when when Prasad was there and and and when Makary was there, they weren't getting a fair shot.
- 15:04Speaker 1: It was um that there were figures that were on the on the scales.
- 15:07Speaker 1: And I think there's a pretty good chance that they will be getting a fair shot uh at at FDA.
- 15:12Speaker 1: I think we're gonna start seeing advisory committee meetings.
- 15:15Speaker 1: One of the ones that I'm gonna be very interested to see what happens is the upcoming meeting on Replimune RP1.
- 15:21Speaker 1: Um, that's oncolytic virus.
- 15:23Speaker 1: You know, I think that uh, you know, that one got two or did it get three um complete response, CRLs, complete response letters.
- 15:32Speaker 1: There's a tremendous amount of controversy about it.
- 15:34Speaker 1: Uh the the Wall Street Journal is uh you know saying that obviously it should be approved, the the good doctors who run the editorial board at the Wall Street Journal.
- 15:43Speaker 1: Um the uh uh you know the the CEO of the of Replimune has been in speaking with FDA leadership about it.
- 15:51Speaker 1: There's gonna be an advisory committee meeting.
- 15:53Speaker 1: I don't personally have an opinion one way or the other uh about whether it should be approved or not, but I think that what's gonna be really important is to see whether whatever action is taken is done in a transparent way where people feel that um it's it's a science-based decision.
- 16:08Speaker 1: The thing that's gonna be really key to look at is who is on the advisory committee that that um that makes that recommendation.
- 16:16Speaker 1: The interesting thing is that FDA is not taking it to the ODAC, which you would have expected for something like this.
- 16:21Speaker 1: They're taking it to the Cell and Gene Therapy Advisory Committee.
- 16:25Speaker 1: It's a cell therapy, so they can they can justify they can they can they can do that.
- 16:30Speaker 1: In the past, when there have been products that are very similar to this, they've been joint committees of of the cell and gene therapy and and and the ODAC.
- 16:38Speaker 1: I think that's a that's kind of a formality, but what's really gonna be important because the the the roster of the cell and gene therapy advisory committee is way down because these committees have kind of atrophied right over the last year and a half because they haven't been used.
- 16:51Speaker 1: So what's gonna be really important is to see two things.
- 16:54Speaker 1: One is who gets appointed as a sp as a you know temporary voting member of the committee who's gonna make this decision?
- 17:00Speaker 1: Are they people that really have the proper expertise?
- 17:02Speaker 1: And two, who presents from FDA and you know, are they you know, are they is there a sense that career staff have been able to present their their own views?
- 17:15Speaker 1: My opinion is I think career staff will be able to present um their views.
- 17:19Speaker 1: I don't think that there's gonna be a finger on the scale that way.
- 17:22Speaker 1: The real question is gonna be who who's gonna be on the committee and are they gonna have the requisite expertise to to one, to give the correct advice, and two, to have the credibility that the public and the um physician community needs.
- 17:37Speaker: That goes back to what some of the things we said in the beginning about conversation is instilling confidence.
- 17:42Speaker: Um, and so this could be some a signal one way or the other.
- 17:45Speaker: Yeah, the two aspects you made, right?
- 17:47Speaker: The who's presenting and then who's on the committee.
- 17:49Speaker: You mentioned something, uh the combination of transparency and complete response letter, CRLs.
- 17:55Speaker: The FDA has been flipping a coin on whether or not CRLs should be public every day now for the last couple of weeks.
- 18:02Speaker: So one day they are public, the next day they're not, back and forth.
- 18:06Speaker: Where what is going on there?
- 18:08Speaker: Why the hesitation and what do you believe the CRL should be public?
- 18:13Speaker 1: You know, what's going on is is just um it's a continuation of the chaotic policy making that we saw under um Marty Makary.
- 18:22Speaker 1: So every commissioner for the last 20 years has considered publishing CRLs.
- 18:28Speaker 1: I've spoken with most of them, they've all looked at it, and their um their legal counsel has all said, told them really, you can't do it.
- 18:36Speaker 1: It's not legal, you can't just do it.
- 18:37Speaker 1: Um the the the FDA regulations say that FDA can't even disclose the existence of an NDA or a uh BLA or even an IND prior to uh approval.
- 18:48Speaker 1: And it's hard to see how you can release a CRL without without revealing the existence of a of a product, right?
- 18:55Speaker 1: So so there's a there's a there's a case that people have made in the past that whether or not this is fits the public good or not, you can't do it unless Congress gives you the authority to do it.
- 19:06Speaker 1: Marty Makary didn't pay attention to that, he just did it.
- 19:09Speaker 1: Then uh Covington Burling, a very uh prominent law firm in Washington, filed a citizen's petition which read an awful lot like a draft for a lawsuit, um telling FDA that you cannot do this and enumerating many reasons in law um why you can't do it, and also making the case.
- 19:27Speaker 1: They're saying that they said that they believed that FDA hadn't properly redacted confidential and proprietary information from the um CRLs for unapproved drugs.
- 19:38Speaker 1: We're really only talking about CRLs for unapproved drugs.
- 19:40Speaker 1: The ones for approved drugs that's not controversial.
- 19:42Speaker 1: So Covington Burling made the case to say that um FDA um didn't that lacked the legal authority to release these in the first place, and even if it was going to do it, that it wasn't um it wasn't undergoing, it wasn't under they weren't undergoing a rigorous enough scrub for um proprietary and confidential information.
- 19:59Speaker 1: So that happened in April.
- 20:01Speaker 1: FDA paused um the release of those um CRLs uh in April.
- 20:07Speaker 1: They stopped, they stopped doing them, all of a sudden there were no more coming out.
- 20:10Speaker 1: Uh that was, I think, the last week, the beginning of last week, if I'm remembering my my time, everything blurs together, but I think it was beginning of last week.
- 20:18Speaker 1: You know, I spoke with um uh uh an HHS spokesperson who said, yeah, we've paused these, it's not happening.
- 20:25Speaker 1: Um, as has kind of been HHS's want in this administration, they uh the spokesperson didn't want to go on the record, they didn't want to have their name used, but they said on background, yeah, we're we're not doing it anymore.
- 20:35Speaker 1: And then three days later, another batch comes out.
- 20:39Speaker 1: And I said, and I contacted them and they said, Well, yeah, yeah, now we're doing it.
- 20:43Speaker 1: We're doing it again.
- 20:43Speaker 1: Lawyers who I spoke with, and one of them, uh, you know, uh Eva uh Temkin and Arnold Porter, I quoted my story, said, you know, she was just flabbergasted by this.
- 20:52Speaker 1: I don't think she said flabbergasted by my story, but she said something along those lines.
- 20:55Speaker 1: She said, you know, it it's it's really surprising, you know.
- 20:58Speaker 1: Um there there really is a strong sense that uh whether or not it's good public policy, it it just isn't legal right now to do it.
- 21:06Speaker 1: There are things that you might think are are good public policy or good to do, but if it's not legal, you can't do them, right?
- 21:12Speaker 1: Um so FDA's been all over the place.
- 21:15Speaker 1: They've said that they're gonna ask Congress for explicit um for explicit authority to release these.
- 21:20Speaker 1: And then they've said that they've just going ahead and doing it anyway.
- 21:23Speaker 1: So it's kind of weird.
- 21:24Speaker 1: And then they have a rule, also they have a rule that's pending um at O'Ra, at OMB, uh, that would uh set out the parameters for being able to release them.
- 21:33Speaker 1: And in the little blurb about the rule, they even say themselves, you know, FDA doesn't really have the authority to do this until we get this rule.
- 21:40Speaker 1: Now that's the purpose of the rule.
- 21:42Speaker 1: And then they're doing it anyway.
- 21:44Speaker 1: So go figure.
- 21:45Speaker 1: I don't know what's gonna happen.
- 21:47Speaker: This is not one of those examples that's gonna instill confidence uh in the community on on what's going on.
- 21:53Speaker 1: And and and and and and besides the fact that there's there's controversy over whether they're um Whether they're redacting everything that they should be redacting, there's also a kind of an element of arbitrariness about which ones do they decide to release and which ones they don't.
- 22:10Speaker 1: And it matters because if these are unapproved products, and many, probably in most cases, the sponsors of those products are engaged in active discussions with FDA, trying to figure out what is what is it that they need to do to be able to get these things approved.
- 22:26Speaker 1: And so if FDA releases a CRL, it can it can destroy investor confidence.
- 22:34Speaker 1: It can destroy patient confidence.
- 22:37Speaker 1: Patients can patients read these things.
- 22:39Speaker 1: They're very, especially in patient groups, they're very sophisticated.
- 22:42Speaker 1: I can tell you, if you have a serious disease or you have a loved one who has a serious disease, you're spending a lot of time with Claude or ChatGPT trying to figure out what the hell is going on and what what's in the pipeline, what's going to help me.
- 22:55Speaker 1: And if you see one of these CRLs for an unapproved product, you can interpret this in ways that may not be accurate.
- 23:05Speaker 1: It's very deflating.
- 23:06Speaker 1: It would be very deflating.
- 23:08Speaker 1: I can see the public health arguments for releasing them.
- 23:12Speaker 1: If there's something that a company's done, I don't know, say a trial design that they've done that FDA said, you know, this trial design for this indication is simply not acceptable.
- 23:21Speaker 1: Well, that can be really valuable information for companies that are developing other drugs for that uh indication, and they would avoid a lot of wasted time.
- 23:31Speaker 1: They've avoid exposing patients perhaps to a drug that's not going to get approved in a in a in a particular design.
- 23:37Speaker 1: So you can make good arguments for releasing these, but it has to be done.
- 23:41Speaker 1: It's really a thicket of competing ideas.
- 23:45Speaker 1: It has to be done really thoughtfully, and they have to solicit advice from the patient community, especially, from the companies, from the lawyers, so that they do it properly.
- 23:56Speaker 1: And just kind of like you said, flipping coins and doing it now and not doing it now, it really doesn't serve anybody well.
- 24:04Speaker: Well, you just described the complete antithesis of the way they they've been behaving in a lot of ways.
- 24:09Speaker: But so Steve, let's say a CEO calls you, they're in the middle towards the end of phase two, head into a phase three trial, and they say, Steve, help me understand how to navigate the FDA over the next 18 months.
- 24:26Speaker: What advice would you give to that to that individual?
- 24:29Speaker 1: Well, the first thing I tell him is subscribe to BioCentry.
- 24:32Speaker 1: The second thing I tell them is call Jayson.
- 24:35Speaker 1: He knows everything.
- 24:36Speaker 1: He's a great consultant.
- 24:38Speaker 1: And uh, you know, and uh you know, and it's interesting.
- 24:44Speaker 1: So I did get, I do get sometimes I do get calls from people like that.
- 24:47Speaker 1: And and that's what I tell them.
- 24:48Speaker 1: I tell them by side by subscription to BioCentury and hire Jayson.
- 24:52Speaker 1: Uh but but you know, and and and under McCarry, you know, people were asking me questions like, should I put somebody who's close to Kennedy on my board?
- 25:01Speaker 1: You know, or should it should or how do I get a line into the to the White House, you know.
- 25:06Speaker 1: Now I don't think that people are asking those questions.
- 25:09Speaker 1: I at least I hope that that's not really the way that people are approaching these things.
- 25:13Speaker 1: I I think that now I think people have to um to think about it.
- 25:19Speaker 1: They have to think about the you know the priorities um uh of the FDA and and of the administration.
- 25:27Speaker 1: I think there's a there's a real um desire.
- 25:30Speaker 1: Uh it's it's explicit that FDA said that they want to push forward on uh drugs for ultra-rare conditions, especially uh really, really rare conditions N of one, for example, or N of nothing really turns out to be N of one, but we call it N of one, it turns out to be N of a few.
- 25:45Speaker 1: But you know, really um those kinds of conditions, I think there's a lot of of um enthusiasm at FDA for finding ways to get those kinds of drugs approved.
- 25:56Speaker 1: Um I think that there's a lot of interest um at at FDA in advancing um supply chain resilience, you know, for um uh drugs that are um tested and manufactured in the United States.
- 26:10Speaker 1: I don't think it's gonna be an explicit uh approval criteria, but I do think that it you know it's possible that it will be taken into consideration in um in in discussions with FDA.
- 26:21Speaker 1: I think having respect for the staff, I think so.
- 26:25Speaker 1: Here's one thing that I've heard from very senior people, career staff at FDA, which is that under Makary and Prasad, CEOs were kind of given free reign to call center directors up and even to call um reviewers up and and and and interact with them.
- 26:43Speaker 1: Um and pressure and and press yeah, off the record, uh, you know, ex parte, as they say, the legal community, and pr and pressure them.
- 26:50Speaker 1: And um and and I've heard from people at FDA that that people who had done that in the in under this previous regime continue to try to do it, and it's created a great deal of anxiety in FDA.
- 27:05Speaker 1: So that one of the things I would say if people ask me that is don't do it, you know?
- 27:09Speaker 1: Don't don't don't um don't you know maybe it worked um in the previous under the previous commissioner.
- 27:17Speaker 1: I I don't think it's gonna work under this commissioner, and I think it's gonna backfire if people try to do those kinds of things.
- 27:23Speaker: What would you say uh to the investor?
- 27:25Speaker: Says, hey Steve, because I know you talk to that community as well.
- 27:28Speaker: Steve, I've got I'm gonna think about investing here, or I've got an investment here, they're in phase two.
- 27:35Speaker: How do I manage the board or how do I man what do I do?
- 27:39Speaker: You know, what same same sort of series of questions.
- 27:42Speaker: How do I think about the FDA?
- 27:44Speaker: If I'm the investor, they ask you that question in the future here.
- 27:48Speaker 1: Uh well, again, subscribe Bio century, Jayson.
- 27:51Speaker 1: But after you've done that, you know, I you know, I think and I hope that the kind of due diligence and the kind of processes that investors have to think about at FDA now is getting back to what they would have thought about prior to January 2025.
- 28:09Speaker 1: I think that's just I I hope and I think that that's the same kind of issue.
- 28:13Speaker 1: And I think that the kinds of issues that they have to deal with now at FDA are more around questions about um expertise.
- 28:22Speaker 1: You know, if you're thinking about oncology, for example, uh an awful lot of of really talented people who have been there um, you know, for many years ha have left O O C E and Cedar and Cebr um divisions that were that were were reviewing cancer drugs.
- 28:39Speaker 1: So I think that it may be that there's a need for more um kind of hand holding or kind of relationship building um at at this at those um centers that they might not have had uh in in the past.
- 28:53Speaker 1: But I think it's a a reversion to normality.
- 28:56Speaker 1: But that's kind of like fingers crossed, right?
- 28:57Speaker 1: Because like we talked about before, we'll see what happens when we get a new commissioner in and a new uh new uh either new or the current um center directors um uh made permanent.
- 29:08Speaker: You know, that's that's good news, Steve, that you think that we are closer to normal than we were, you know, a couple of months ago, that the pendulum is swinging back into some kind of normalcy, as we like to say here, regular order, and and we have some um some normal processes here.
- 29:26Speaker: So um as as we start wrapping up here uh our conversation, which I I greatly appreciate, give me two or three more sound bites of optimism here.
- 29:38Speaker: I'd like to leave on a positive note.
- 29:40Speaker: What else do you think um the FDA is doing that you didn't mention before that should give patients, of course, and others in the communities optimism that maybe that pendulum is still going?
- 29:51Speaker: What other initiatives?
- 29:53Speaker: You mentioned ODAX are coming back, you mentioned First and Human Trial.
- 29:57Speaker: Uh what else are is there anything related to maybe you want to talk about food if you cover that side of FDA, uh elimination of animals, uh testing in animals.
- 30:07Speaker: What else is there that the FDA is doing that we should feel good about?
- 30:12Speaker 1: You know, on the food side, I I the only thing I know about food is I like to eat it.
- 30:15Speaker 1: You know, I don't I don't know anything about it.
- 30:17Speaker 1: Yes, food.
- 30:18Speaker 1: You know, and and and to be honest, if if it were up to me, and I and I wrote a long, a long um series of stories about this, it's up to me, foods would be separate and tobacco would be separate.
- 30:27Speaker 1: We just have a medical products agency because that's enough for any person to run.
- 30:30Speaker 1: So you mentioned um animal testing.
- 30:32Speaker 1: There there is a uh you know, this is a an initiative that's been going on that goes back before, of course, before the Trump administration goes back many years, uh, to try to come up with new analytical methods um that avoid animal testing, not only because of the issues around uh people's concerns about the ethical issues around concern testing animals, but because they're it's they're they're not very accurate, right?
- 30:54Speaker 1: Um toxicology testing and animals isn't very accurate.
- 30:57Speaker 1: Um the efficacy side of it's even less accurate.
- 30:59Speaker 1: You can cure mice or rats or just about anything, um, but it does, you know, it doesn't, it doesn't um it doesn't it's all too often it doesn't translate to humans.
- 31:08Speaker 1: So there's a big push at FDA um to try to um validate um and to facilitate industry validating um non-animal methods.
- 31:17Speaker 1: Um I think there's a what there's a new acronym for NAM, but that but that's what it is.
- 31:22Speaker 1: Um so I I think that's definitely um something that's positive.
- 31:27Speaker 1: I think that FDA is embracing AI.
- 31:31Speaker 1: Look, everybody in our lives is embracing AI if we like it or not.
- 31:34Speaker 1: Um my sense is that um they're taking that um very seriously, and that you know that kind of one of the silver linings in losing a lot of people is now they're hiring a lot of, they're trying to hire a lot of people.
- 31:47Speaker 1: Uh, and uh they're they're having mixed success.
- 31:49Speaker 1: FDA has always had mixed success when it comes to hiring people.
- 31:52Speaker 1: But anyway, the people that they're hiring, they're looking for people who have expertise in AI and people who are younger who have fluency uh in AI.
- 32:01Speaker 1: That's gonna be, you know, um really important.
- 32:04Speaker 1: I think that um another shift, again, a post-MCA shift, I think, is an openness to collaborating with regulators around the world to try to come up with to you know to bring best practices um in into the United States.
- 32:18Speaker 1: You know, um at Biocentury, we spend a lot of time with regulators in other countries.
- 32:23Speaker 1: Um lately, for example, we've been um speaking with Lawrence Talon, the head of MHRA, the regulator in the UK.
- 32:29Speaker 1: Um they have a lot of forward-thinking ideas.
- 32:32Speaker 1: Um and and and then there's a and and there also has to be, uh, and I think that they're moving forward on this also, much more uh reliance on um foreign regulators for things like inspections, right?
- 32:45Speaker 1: As the industry becomes much, much more globalized and things are manufactured and clinical trials are happening around the world, it's impossible for FDA to be all of the places that it needs to be.
- 32:59Speaker 1: Uh it's not impossible for somebody to be everywhere.
- 33:02Speaker 1: Um and and and so FDA's has to come up with um good ways, and I think that they are working on this, to r to be more reliant on um European regulators, on um on the UK, on um advanced regulators in um in Asia, um, so that we can you know so we can have better ideas um and better better insights into the quality of manufacturing, you know, because there have been really serious problems in the past about um drug qual uh the quality of drug manufacturing.
- 33:37Speaker 1: Um and that's that's something that everybody has to be um uh uh concerned about.
- 33:41Speaker 1: So that's a positive sign.
- 33:43Speaker 1: I think I think the fact that FDA isn't in the news so much anymore is also you know a positive sign.
- 33:50Speaker 1: It's again, it's a shift towards going back to kind of more uh normality.
- 33:55Speaker 1: I think that what's needed is is something that's more transform transformative going forward.
- 34:01Speaker 1: I think again, I think that we need to have um an independent medical products regulator that's separate from food and um tobacco.
- 34:10Speaker 1: Um I think we need to have um leadership that um is expected to last more than one administration, so it's not a political job.
- 34:18Speaker 1: And I think we need to create the kind of uh environment where people feel good about going to FDA, where they feel that as they have in the past, that it it's a public s a public health agency that's um that's really benefiting um everybody, and that that's a career path for people who want to be able to make a positive change, to have positive impact on things.
- 34:44Speaker 1: I hope and I think that maybe we are getting back to that that that sense, and that that's really important.
- 34:51Speaker: Well, see, that's a great way to conclude our discussion.
- 34:55Speaker: Some optimism, some um forward thinking, some positivity there.
- 34:59Speaker: We've been through 18 months, as you've just well described, some tumultuous times, and I I do actually share your optimism.
- 35:08Speaker: I think we are back on the pendulum upswing uh with the FDA.
- 35:13Speaker: I agree with you about being out of the news is great, no news is good news.
- 35:17Speaker: Um, and just let them get back to regular order.
- 35:20Speaker: And like you, I'm curious to see.
- 35:22Speaker: I represent a couple of gene therapy companies.
- 35:25Speaker: Uh curious to see how they they've been invited back in, how that all goes.
- 35:29Speaker: But um, and also I think post-election, when we get some normalcy from the top down, I think that'll that that'll help as well.
- 35:36Speaker 1: So I really think we're that you're more optimistic than I am about normalcy from the top down.
- 35:42Speaker 1: It depends on how high up to the top you're talking about.
- 35:45Speaker: The next Secretary of Health will be more mainstream than the current secretary.
- 35:50Speaker 1: I agree.
- 35:50Speaker 1: I I think that that's the case.
- 35:51Speaker 1: And and and I think that Chris, look, I touched on it before.
- 35:55Speaker 1: Chris Clump is making a lot of the operational decisions now, and um, and he's somebody everybody you agree or disagree with particular decisions that he's made, but everybody I know who's um who's interacted with him or been affected by the decisions he's made, uh, you know, I've said that this is a person who who's who has the interests of the American people and public health in mind, and he and he's doing things, as you said, regular order.
- 36:19Speaker 1: He's kind of a regular order kind of guy.
- 36:21Speaker 1: Um, and and that's really very positive.
- 36:24Speaker: Yeah, it's it's less fire ready aim, it's a little bit more ready aim.
- 36:27Speaker: Like there is some thought when it's there.
- 36:29Speaker 1: Yeah.
- 36:29Speaker: Um, and the you know, we will we could have another discussion about most favorite issue on the reimbursement side on that, but we'll we'll we'll save that for the for the next podcast.
- 36:38Speaker 1: That won't be fun.
- 36:39Speaker: But um, thank you so much for your time.
- 36:41Speaker: I really appreciate it.
- 36:42Speaker: Like I said, it was an honor for me to host you here uh on uh this this issue of value-based voices.
- 36:49Speaker: You are always welcome to come back.
- 36:52Speaker: And um, you know, we could always switch around.
- 36:54Speaker: Meet the press, you know.
- 36:55Speaker: I I I love this, I love this uh this dynamic.
- 36:58Speaker 1: I've uh yeah, yeah, and I host some podcasts too, so maybe I'll have you on there and we'll we'll switch it around there too.
- 37:03Speaker: Yeah, we'll pick it up from there.
- 37:04Speaker: So thanks a lot, Steve.
- 37:05Speaker: Much appreciated.
- 37:06Speaker: Thanks a lot.
- 37:07Speaker: It's fun.
- 37:08Speaker: That wraps up this episode of Value-Based Voices, brought to you by the Association for Value-Based Cancer Care.
- 37:15Speaker: Thank you very much, Steve, for sharing your insights and to our listeners for joining both conversations.
- 37:21Speaker: If you found today's discussion thought provoking, be sure to subscribe to Value Based Voices wherever you get your podcast.
- 37:28Speaker: Stay tuned for more episodes at Spotlight the Voices Shaping the Future of Oncology.